The global Glaucoma Eye Drops Market is estimated to be valued at US$ 1,666.3 Mn in 2022 and is expected to exhibit a CAGR of 7.3% over the forecast period 2023-2030, as highlighted in a new report published by Coherent Market Insights. 

Market Overview:
Glaucoma eye drops help reduce eye pressure by draining fluid from the eye. They come in the form of solutions, gels, or ointments and are applied topically. Glaucoma eye drops have minimal side effects and help control the condition effectively.

Market key trends:
One of the key trends in the glaucoma eye drops market is the rise in mergers and acquisitions. Major companies are focusing on expanding their glaucoma product portfolios through strategic mergers and acquisitions. For instance, in 2021, Allergan plc, which is a subsidiary of AbbVie Inc., acquired an early-stage antifibrotic compound AT-877 from Anthropic to strengthen its glaucoma pipeline. Similarly, in 2020, Novartis acquired dry eye drug Thea Pharmaceuticals to expand its portfolio of eye care products. Such strategic deals allow companies to fast track new product development and commercialization.

Segment Analysis
The global glaucoma eye drops market is segmented into prescription drugs and OTC drugs. Prescription drugs dominate the market and accounted for nearly 70% share in 2023. This is because prescription drugs contain higher concentration of active pharmaceutical ingredients that are specifically prescribed for a patient based on the severity of glaucoma condition. Within prescription drugs, prostaglandin analogs sub-segment held the largest market share owing to its high efficacy and long durations of action in lowering intraocular pressure. 

Key Takeaways 
The Global Glaucoma Eye Drops Market size was valued at US$ 1,666.3 Mn in 2023 and is expected to reach US$ 2,293.4 Mn by 2030, expanding at a CAGR of 7.3% from 2023 to 2030. Increasing prevalence of glaucoma, rising geriatric population, and growing awareness about eye diseases are expected to drive the market during the forecast period.

The US dominated the global market in 2023 and accounted for over 40% of the global revenue share due to strong presence of pharmaceutical companies and growing glaucoma patient pool. Asia Pacific region is anticipated to witness fastest growth over the next few years supported by increasing healthcare spending, large population base and growing medical tourism industry in the region. 

Key players operating in the glaucoma eye drops market are Merck KGaA, Allergan plc (A subsidiary of AbbVie Inc.), Novartis AG, Teva Pharmaceutical Industries Ltd., Pfizer, Inc., Bausch & Lomb, Inotek, Jadran-galenski laboratorij d.d. JGL d.d, Aerie Pharmaceutical (A subsidiary of Alcon Management S. A) and Mylan N.V (A subsidiary of Viatris Inc.). These players are engaged in new product launches, collaborations and geographic expansion strategies to strengthen their market position.
Read More:
https://www.marketwebjournal.com/glaucoma-eye-drops-market-growth-size-a...